AL
ALEC.US Alector Inc
- Market cap
- USD 378M
- P/E
- 6.9x
- P/B
- 3.13x
- ROE
- 90.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALEC.US undervalued?
Graham numberALEC.US trades 2.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alector Inc fundamental analysis
No fundamental analysis for Alector Inc yet.
Alector Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical devel…
Full company profileAlector Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alector Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 416K | 3.74M | 27.7M | 21.2M | 21.1M | 207M | 134M | 97.1M | 101M | 21.0M | 223M |
| Gross Profit | -13.3M | -26.2M | 27.7M | 21.2M | 21.1M | 207M | 134M | 88.2M | -85.4M | 11.4M | 223M |
| Operating Income | -15.1M | -32.7M | -57.3M | -114M | -195M | -37.4M | -138M | -152M | -145M | -146M | 99.4M |
| EBITDA | -14.9M | -32.0M | -56.3M | -109M | -188M | -29.0M | -129M | -116M | -110M | -133M | 109M |
| Net Income | -15.1M | -32.5M | -52.2M | -99.8M | -183M | -28.0M | -133M | -130M | -119M | -143M | 105M |
| EPS | -1.78 | -0.63 | -0.76 | -1.62 | -2.35 | -0.35 | -1.62 | -1.56 | -1.23 | -1.39 | 0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 54.1M | 236M | 308M | 422M | 488M | 815M | 788M | 622M | 468M | 293M | 166M |
| Total Liabilities | 79.0M | 288M | 406M | 227M | 221M | 514M | 573M | 488M | 342M | 263M | 49.2M |
| Shareholders' Equity | -24.9M | -52.0M | -97.4M | 195M | 268M | 301M | 214M | 134M | 127M | 30.6M | 117M |
| Cash & Short-term Investments | 50.8M | 32.5M | 290M | 353M | 413M | 735M | 713M | 549M | 413M | 256M | 139M |
| Total Debt | - | - | - | 48.0M | 51.3M | 47.6M | 43.3M | 38.9M | 42.5M | 36.2M | 21.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.0M | -17.8M | 127M | -99.3M | -167M | 299M | -20.3M | -184M | -230M | -184M | -144M |
| Capital Expenditure | 2.25M | 801K | 1.88M | 15.3M | 5.03M | 3.25M | 4.12M | 2.38M | 1.26M | 41.0K | 199K |
| Free Cash Flow | -15.2M | -18.6M | 126M | -115M | -172M | 295M | -24.4M | -187M | -231M | -184M | -144M |
| Ratios | |||||||||||
| ROE | - | - | - | -51.3% | -68.4% | -9.3% | -62.2% | -97.2% | -93.9% | -466.3% | 90.0% |
| ROA | -27.9% | -13.8% | -16.9% | -23.7% | -37.5% | -3.4% | -16.9% | -21.0% | -25.4% | -48.7% | 63.3% |
| Net Profit Margin | -3,632.2% | -869.6% | -188.8% | -470.4% | -867.2% | -13.5% | -99.8% | -134.3% | -118.4% | -679.2% | 47.0% |
| Debt to Equity | - | - | - | 0.25x | 0.19x | 0.16x | 0.20x | 0.29x | 0.34x | 1.18x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alector Inc dividends
Alector Inc has not paid dividends in the last 9 fiscal years.
Who owns Alector Inc
- Insiders 7.35%
- Institutions 82.90%
- Public & others 9.75%
- Shares outstanding 149M
- Free float 102M
Top funds holding ALEC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.84M | 1.91% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.49M | 1.67% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 940K | 0.63% | -11.87% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 830K | 0.56% | -0.38% | Oct 2026 |
| Vanguard Explorer Inv | 673K | 0.45% | 0.00% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 629K | 0.42% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 539K | 0.36% | -4.38% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 505K | 0.34% | +0.23% | Oct 2026 |
| Vanguard VIF Small Co Gr | 495K | 0.33% | -19.66% | Sep 2026 |
| Fidelity Extended Market Index | 453K | 0.30% | +26.02% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 344K | 0.23% | +3.25% | Aug 2026 |
| iShares Micro-Cap ETF | 280K | 0.19% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 239K | 0.16% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 233K | 0.16% | +0.11% | Sep 2026 |
| Fidelity Total Market Index | 195K | 0.13% | +19.97% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 187K | 0.13% | -1.85% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 167K | 0.11% | -14.77% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 151K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 145K | 0.10% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 141K | 0.09% | +253.91% | Oct 2026 |
Top institutions holding ALEC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 10.0M | 8.96% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 8.64M | 7.73% | +206.69% | Jun 2026 |
| BlackRock Inc | 7.85M | 7.03% | +1.38% | Jun 2026 |
| Acadian Asset Management LLC | 4.41M | 3.95% | +9.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.01M | 3.59% | +8.99% | Jun 2026 |
| Kynam Capital Management, LP | 3.81M | 3.41% | +90.42% | Jun 2026 |
| Merck & Co Inc | 3.55M | 3.18% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 3.25M | 2.91% | +10.64% | Jun 2026 |
| D. E. Shaw & Co LP | 2.96M | 2.65% | -11.19% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.88M | 2.58% | +174.63% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.82M | 2.53% | +9.17% | Jun 2026 |
| Geode Capital Management, LLC | 2.45M | 2.20% | +7.35% | Jun 2026 |
| Spruce Street Capital LP | 2.10M | 1.88% | 0.00% | Jun 2026 |
| Millennium Management LLC | 1.99M | 1.78% | +0.49% | Jun 2026 |
| Ikarian Capital, LLC | 1.98M | 1.78% | -4.80% | Jun 2026 |
| State Street Corp | 1.88M | 1.68% | +0.76% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.77M | 1.58% | -18.03% | Jun 2026 |
| Medici Capital LLC | 1.65M | 1.48% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.51M | 1.35% | +202.00% | Jun 2026 |
| Eversept Partners, LP | 1.42M | 1.28% | +5.39% | Jun 2026 |
Alector Inc company profile
- Company name
- Alector Inc
- Ticker
- ALEC.US
- Exchange
- USA Stocks
- Listed since
- Feb 7, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Fiscal year end
- December
- Address
- 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 415 231 5660
- Website
- alector.com
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector Inc management
9- Dr. Arnon Rosenthal Ph.D.Co-Founder, CEO & Director · born 1956
- Mr. Neil Berkley M.B.A., M.S.CFO & Chief Business Officer · born 1974
- Ms. Grace Wong-SaradChief Accounting Officer & Principal Accounting Officer
- Ms. Katie HoganSenior Director of Corporate Communication & Investor Relations
- Ms. Danielle Pasqualone J.D., Ph.D.General Counsel
- Ms. Clare Hunt M.B.A.Chief People & Places Officer
- Dr. Hua Long DABT, Ph.D.Senior VP & Head of Research
- Dr. Caiyan Li Ph.D.Head of Clinical Development & Data Science
- Dr. Eric Brown Ph.D.Director of Antibody Discovery & Protein Engineering